Wedbush lowered the firm’s price target on Denali Therapeutics to $30 from $31 and keeps an Outperform rating on the shares. Overall, the Q1 financial results update for Denali was largely as anticipated, the firm says. Most notable, Denali reiterated all major timelines remain on track, adds Wedbush.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNLI:
- Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
- Denali completes enrollment for Regimen G of Phase 2/3 HEALEY ALS trial
- Denali Therapeutics price target lowered to $32 from $70 at UBS
- Denali Therapeutics files to sell 29.29M shares of common stock for holders